Journal: Cell Reports Medicine

Article Title: The single-cell transcriptional landscape of innate and adaptive lymphocytes in pediatric-onset colitis

doi: 10.1016/j.xcrm.2023.101038

Figure Lengend Snippet:

Article Snippet: anti-human CRTH2 PE-CF594 (Clone BM16) , BD , Cat#563501.

Techniques: Software, Staining

Journal: Immunity, Inflammation and Disease

Article Title: Interleukin‐25 initiates Th2 differentiation of human CD4 + T cells and influences expression of its own receptor

doi: 10.1002/iid3.87

Figure Lengend Snippet: IL‐25R is highly expressed by in vitro differentiated CRTh2 + Th2 cells. Flow cytometry of (A) surface CRTh2 (solid line) compared with isotype control (dotted line; day 42) and (B) intra‐cellular IL‐4, IL‐13 and IFN‐γ⋅ (C) qRT‐PCR for IL‐25R mRNA from activated CRTh2 + Th2 cells (day 45, black bar, n = 6 independently differentiated lines) were compared with activated non‐polarized CD4 + T cells (day 3, white bar, 61‐fold, n = 5). (D) Representative example of surface IL‐25R expression (solid line) compared to isotype control (dotted line) by differentiated CRTh2 + Th2 cells (day 43) and (E) kinetics of surface IL‐25R expression following TCR activation ( n = 4, three independently differentiated lines). Statistical significance was determined by Student's t test, * P < 0.05.

Article Snippet: Complementary DNA (cDNA) was synthesized from 1 μg of RNA using the Superscript II Reverse Transcriptase according to manufacturer's instructions (Cat #18964‐014, Invitrogen, Burlington, ON, Canada). qRT‐PCR TaqMan gene expression assays for CRTh2 (Hs00173717_m1), IL‐25R (Hs00218889_1) and IL‐4 (Hs00174122_m1) were purchased from Applied Biosystems (Burlington, On, Canada).

Techniques: In Vitro, Flow Cytometry, Control, Quantitative RT-PCR, Expressing, Activation Assay

Journal: Immunity, Inflammation and Disease

Article Title: Interleukin‐25 initiates Th2 differentiation of human CD4 + T cells and influences expression of its own receptor

doi: 10.1002/iid3.87

Figure Lengend Snippet: IL‐25 mediates acquisition of the Th2 phenotype. Naïve CD4 + T cells were differentiated in non‐polarizing (NP) control conditions (αCD3/αCD28, IL‐2, αIFNγ and αIL‐12) or NP + IL‐4 (IL‐4), NP + IL‐25 (IL‐25) or NP + IL‐4 and IL‐25 (IL‐4+IL‐25). (A) IL‐25R mRNA expression (fold increase over NP; day 3, 7, 10, 14, n = 10 of three independently differentiated lines). (B) Intracellular IL‐4 and (E) surface CRTh2 were assayed following proliferation (day 7, 14, n = 17, 10 independently differentiated lines). (D) GATA3 was assayed after stimulation (day 3, 10, n = 17, 10 independently differentiated lines). (C) IL‐4 mRNA expression by cells cultured in IL‐4 or IL‐25 (fold increase over NP, day 14; n = 4 independently differentiated lines). (F) Cell counts were determined and comparison was made between the four conditions for each day. Statistical significance determined by repeated measures ANOVA, * P < 0.05.

Article Snippet: Complementary DNA (cDNA) was synthesized from 1 μg of RNA using the Superscript II Reverse Transcriptase according to manufacturer's instructions (Cat #18964‐014, Invitrogen, Burlington, ON, Canada). qRT‐PCR TaqMan gene expression assays for CRTh2 (Hs00173717_m1), IL‐25R (Hs00218889_1) and IL‐4 (Hs00174122_m1) were purchased from Applied Biosystems (Burlington, On, Canada).

Techniques: Control, Expressing, Cell Culture, Comparison

Journal: Immunity, Inflammation and Disease

Article Title: Interleukin‐25 initiates Th2 differentiation of human CD4 + T cells and influences expression of its own receptor

doi: 10.1002/iid3.87

Figure Lengend Snippet: Regulation of IL‐25R on Th2 cells. Differentiated CRTh2 + Th2 cells were cultured with IL‐2 in the presence or absence of IL‐25 and stained for (A) IL‐25R ( n = 5, three independently differentiated cell lines) or assessed for (B) IL‐25R mRNA levels ( n = 3). (C) Surface expression of IL‐25R on CRTh2 + Th2 cells treated (24 h) with a CRTh2 agonist (DK‐PGD 2 ) or IL‐2 ( n = 4). Statistical significance determined by paired t test within each time point (A, B) or between conditions (C), * P < 0.05.

Article Snippet: Complementary DNA (cDNA) was synthesized from 1 μg of RNA using the Superscript II Reverse Transcriptase according to manufacturer's instructions (Cat #18964‐014, Invitrogen, Burlington, ON, Canada). qRT‐PCR TaqMan gene expression assays for CRTh2 (Hs00173717_m1), IL‐25R (Hs00218889_1) and IL‐4 (Hs00174122_m1) were purchased from Applied Biosystems (Burlington, On, Canada).

Techniques: Cell Culture, Staining, Expressing

Journal: Immunity, Inflammation and Disease

Article Title: Interleukin‐25 initiates Th2 differentiation of human CD4 + T cells and influences expression of its own receptor

doi: 10.1002/iid3.87

Figure Lengend Snippet: IL‐25 slows re‐expression of CRTh2 on Th2 cells following TCR activation. (A) Differentiated CRTh2 + Th2 cells cultured with IL‐2, αCD3 and αCD28 exhibited time dependent loss of surface CRTh2 expression ( n = 4, two independently differentiated cell lines). (B–G) CRTh2 + Th2 cells were cultured with IL‐2, αCD3 and αCD28 (24 h) and then placed with IL‐2 in the presence or absence of IL‐25 (another 24 h). % of cells expressing (B) CRTh2, (D) CD62L or (F) CCR4 and mean fluorescent intensity (MFI) for (C) CRTh2, (E) CD62L and (G) CCR4 were quantified ( n = 6, two independently differentiated lines). Statistical significance was determined by paired t test (B–G), * P < 0.05.

Article Snippet: Complementary DNA (cDNA) was synthesized from 1 μg of RNA using the Superscript II Reverse Transcriptase according to manufacturer's instructions (Cat #18964‐014, Invitrogen, Burlington, ON, Canada). qRT‐PCR TaqMan gene expression assays for CRTh2 (Hs00173717_m1), IL‐25R (Hs00218889_1) and IL‐4 (Hs00174122_m1) were purchased from Applied Biosystems (Burlington, On, Canada).

Techniques: Expressing, Activation Assay, Cell Culture

Journal: eLife

Article Title: Single-cell glycomics analysis by CyTOF-Lec reveals glycan features defining cells differentially susceptible to HIV

doi: 10.7554/eLife.78870

Figure Lengend Snippet:

Article Snippet: Antibody , Anti-Human CD294/CRTH2 (BM16) (Rat, Monoclonal) , Fluidigm , Cat# 3163003B , CyTOF (1:50).

Techniques: Recombinant, Plasmid Preparation, Software

Journal: Science Advances

Article Title: CHI3L1/YKL-40 signaling inhibits neurogenesis in models of Alzheimer’s disease

doi: 10.1126/sciadv.adv1492

Figure Lengend Snippet: ( A ) Immunoblots of 17 candidate mediators after 10-min CHI3L1 exposure (0 to 500 ng/ml). Phospho/total signals were densitometrically normalized to the no-CHI3L1 control (1.0); n = 3 to 4. ( B ) Dose-response blots for p-S6K1 and p-S6 (10 min). Values are phospho/total, expressed relative to untreated cells (1.0); n = 4. ( C ) Dose-response blots for p-IKKβ with the same quantification as in (B); n = 3. ( D ) BMS345541 (10 μM, 30 min) was added 10 min before CHI3L1 (500 ng/ml). p-S6 was quantified as in (B); n = 4. ( E ) iNPCs transfected with CRTH2 siRNA (siCRTH2) or control siRNA (siNC) were exposed to CHI3L1 (500 ng/ml, 48 hours). Proliferation = EdU + /DAPI + cells (% of total DAPI + ); n = 4. ( F ) After the same transfection, cells were differentiated for 3 days under CHI3L1 incubation. Neuronal differentiation output = DCX + /DAPI + (%), expressed as fold change over siNC+Ctrl (1.0); n = 4. Statistics: one-way ANOVA with Tukey’s post hoc for [(A) to (C)] and (E); unpaired t test for (D). * P < 0.05; ** P < 0.005, *** P < 0.001; **** P < 0.0001. n.s., not significant.

Article Snippet: To determine the requirement of CRTH2 in the CHI3L1 signaling pathway, we performed RNAi-mediated knockdown of CRTH2 in iNPCs using a validated siRNA targeting human CRTH2 (siCRTH2; Santa Cruz Biotechnology, #sc-39838) or a control siRNA (siCtrl; Santa Cruz Biotechnology, #sc-37007).

Techniques: Western Blot, Control, Transfection, Incubation

Journal: Science Advances

Article Title: CHI3L1/YKL-40 signaling inhibits neurogenesis in models of Alzheimer’s disease

doi: 10.1126/sciadv.adv1492

Figure Lengend Snippet: ( A ) Design and timeline. Lentiviruses expressing shCRTH2-eGFP or shCtrl-eGFP were injected bilaterally into the DG of 6-month-old wild-type (WT) and 5XFAD mice (shCtrl in one side and shCRTH2 in the other). BrdU was given immediately, EdU 24 hours before euthanasia 4 weeks later. Groups: WT + shCtrl, 5XFAD + shCtrl, and 5XFAD + shCRTH2 ( n = 5). ( B ) Thioflavin-S/Aβ 42 staining showed hippocampal plaques in 5XFAD but not WT; CRTH2 knockdown did not change plaque size or density. ( C ) GFAP and CHI3L1 Immunolabeling indicated comparable astrocytosis and CHI3L1 induction in 5XFAD hemispheres with or without shCRTH2. ( D ) SGZ proliferation. EdU+ GFP+ cells were classified as radial NSCs (GFAP+) or amplifying progenitors (GFAP−). Proliferation was reduced in 5XFAD + shCtrl versus WT but significantly restored by shCRTH2. ( E ) Neuronal output. GFP+ BrdU+ cells coexpressing DCX (immature) or NeuN (mature) were decreased in 5XFAD + shCtrl and rescued by CRTH2 knockdown. Scale bars, 100 μm. ** P < 0.005, *** P < 0.001, and **** P < 0.0001 by one-way ANOVA with Tukey’s post hoc (comparisons versus WT + shCtrl and 5XFAD + shCtrl).

Article Snippet: To determine the requirement of CRTH2 in the CHI3L1 signaling pathway, we performed RNAi-mediated knockdown of CRTH2 in iNPCs using a validated siRNA targeting human CRTH2 (siCRTH2; Santa Cruz Biotechnology, #sc-39838) or a control siRNA (siCtrl; Santa Cruz Biotechnology, #sc-37007).

Techniques: Expressing, Injection, Staining, Knockdown, Immunolabeling

Journal: PLoS ONE

Article Title: Chemoattractant Receptor Homologous to the T Helper 2 Cell (CRTH2) Is Not Expressed in Human Amniocytes and Myocytes

doi: 10.1371/journal.pone.0050734

Figure Lengend Snippet: The primer sequences used for amplification of CRTH2.

Article Snippet: Antibodies against phospho-p65 (Ser 536), p65 and CRTH2 for western analysis were purchased from Cell Signaling Technology (Beverly, MA), Santa Cruz Biotechnology (Santa Cruz, CA) or Santa Cruz and ProSci Incorporated (Poway, CA) respectively.

Techniques: Amplification

Journal: PLoS ONE

Article Title: Chemoattractant Receptor Homologous to the T Helper 2 Cell (CRTH2) Is Not Expressed in Human Amniocytes and Myocytes

doi: 10.1371/journal.pone.0050734

Figure Lengend Snippet: The incubation conditions and the catalogue numbers for all antibodies used.

Article Snippet: Antibodies against phospho-p65 (Ser 536), p65 and CRTH2 for western analysis were purchased from Cell Signaling Technology (Beverly, MA), Santa Cruz Biotechnology (Santa Cruz, CA) or Santa Cruz and ProSci Incorporated (Poway, CA) respectively.

Techniques: Incubation

Journal: PLoS ONE

Article Title: Chemoattractant Receptor Homologous to the T Helper 2 Cell (CRTH2) Is Not Expressed in Human Amniocytes and Myocytes

doi: 10.1371/journal.pone.0050734

Figure Lengend Snippet: mRNA was isolated from cultured amniocytes, myocytes, PBMCs, choriodecidual and placental extracts and converted to cDNA (n = 6). Qualitative PCR was used with three primer sets to amplify CRTH2 showing product sizes of 309 bp, 265 bp, and 114 bp. Non-template and reverse transcriptase negative controls were used and mRNA from placenta, choriodecidua and peripheral blood mononuclear cells were used as a positive controls. ( A , B ): Non-template control (lane 1), amniocytes (lane 2), choriodecidua (lane 3), myocytes (lane 4), placenta (lane 5); ( C ): Reverse transcriptase controls (lanes 1,3,5,7,9), PBMCs (lane 2), amniocytes (lanes 4,6), myocytes (lanes 8,10).

Article Snippet: Antibodies against phospho-p65 (Ser 536), p65 and CRTH2 for western analysis were purchased from Cell Signaling Technology (Beverly, MA), Santa Cruz Biotechnology (Santa Cruz, CA) or Santa Cruz and ProSci Incorporated (Poway, CA) respectively.

Techniques: Isolation, Cell Culture, Reverse Transcription, Control

Journal: PLoS ONE

Article Title: Chemoattractant Receptor Homologous to the T Helper 2 Cell (CRTH2) Is Not Expressed in Human Amniocytes and Myocytes

doi: 10.1371/journal.pone.0050734

Figure Lengend Snippet: 50 µg of whole cell lysate from PBMCs, amniocytes, myocytes were subject to western analysis. Membranes were probed with the primary antibody -SC-23092 to detect a Mr∼34 000 product ( A ; Lanes 1–3). The secondary antibody control blot is also shown ( B ; Lanes 1–3). β-actin was used as a loading control. Lane 1 = PBMCs, lane 2 = amniocytes, lane 3 = myocytes. Multiple bands are seen on the blot. A band appears at Mr∼34 000 in amniocytes, faintly in the myocyte lane, but is absent in the positive control PBMCs lane. However, the strongest bands appear at Mr∼15 000 and at just above Mr∼43 000 in all lanes. Myocytes from passage zero, one, two, three and four (lanes 1–5 respectively) were also examined for CRTH2 expression showing a very faint band at Mr∼34 000, with no effect of passage number ( C ).

Article Snippet: Antibodies against phospho-p65 (Ser 536), p65 and CRTH2 for western analysis were purchased from Cell Signaling Technology (Beverly, MA), Santa Cruz Biotechnology (Santa Cruz, CA) or Santa Cruz and ProSci Incorporated (Poway, CA) respectively.

Techniques: Western Blot, Control, Positive Control, Expressing

Journal: PLoS ONE

Article Title: Chemoattractant Receptor Homologous to the T Helper 2 Cell (CRTH2) Is Not Expressed in Human Amniocytes and Myocytes

doi: 10.1371/journal.pone.0050734

Figure Lengend Snippet: The in vitro transcription translation kit was used with 35 S Methionine to demonstrate the expression of CRTH2 and to provide a positive control for detection of CRTH2. A Mr∼34 000 product was detected by x-ray (Lane 2). The progesterone expression vector was used as a control for the TNT kit ( A ). The protein lysate from the TNT kit was subjected to western analysis; Negative Control: TNT kit with no plasmid DNA (lane 1), Negative control: Progesterone PSG5 Expression vector (lane 2), Positive control: 35 S Methionine labelled CRTH2 (Lane 3), Cold Methionine CRTH2 protein product (lane 4). Membranes were probed with 3 commercial antibodies; SC-23092 ( B ), SC-21798 ( C ), ProSci 4027 ( D ). None of the antibodies detected CRTH2.

Article Snippet: Antibodies against phospho-p65 (Ser 536), p65 and CRTH2 for western analysis were purchased from Cell Signaling Technology (Beverly, MA), Santa Cruz Biotechnology (Santa Cruz, CA) or Santa Cruz and ProSci Incorporated (Poway, CA) respectively.

Techniques: In Vitro, Expressing, Positive Control, Plasmid Preparation, Control, Western Blot, Negative Control

Journal: PLoS ONE

Article Title: Chemoattractant Receptor Homologous to the T Helper 2 Cell (CRTH2) Is Not Expressed in Human Amniocytes and Myocytes

doi: 10.1371/journal.pone.0050734

Figure Lengend Snippet: Lymphocytes were gated according to forward scatter and side scatter and T helper cells were identified using CD4 as a cell surface marker (n = 6). A representative cytogram is presented with the right upper quadrant showing CRTH2 + /CD4 + lymphocytes ( A ). Histograms showing no staining, isotype control and CRTH2 + labelled lymphocytes ( B ), amniocytes ( C ) and myocytes ( D ), (n = 5).

Article Snippet: Antibodies against phospho-p65 (Ser 536), p65 and CRTH2 for western analysis were purchased from Cell Signaling Technology (Beverly, MA), Santa Cruz Biotechnology (Santa Cruz, CA) or Santa Cruz and ProSci Incorporated (Poway, CA) respectively.

Techniques: Marker, Staining, Control

Journal: PLoS ONE

Article Title: Chemoattractant Receptor Homologous to the T Helper 2 Cell (CRTH2) Is Not Expressed in Human Amniocytes and Myocytes

doi: 10.1371/journal.pone.0050734

Figure Lengend Snippet: An overview of the mean fluorescence intensities and percentages in the gated cells during detection of endogenous CRTH2 in lymphocytes, amniocytes and myocytes.

Article Snippet: Antibodies against phospho-p65 (Ser 536), p65 and CRTH2 for western analysis were purchased from Cell Signaling Technology (Beverly, MA), Santa Cruz Biotechnology (Santa Cruz, CA) or Santa Cruz and ProSci Incorporated (Poway, CA) respectively.

Techniques: Fluorescence

Journal: PLoS ONE

Article Title: Chemoattractant Receptor Homologous to the T Helper 2 Cell (CRTH2) Is Not Expressed in Human Amniocytes and Myocytes

doi: 10.1371/journal.pone.0050734

Figure Lengend Snippet: Amniocytes ( A ) and myocytes ( B ) were transfected using gene juice and electroporation respectively with CRTH2 PSG5 expression vector and labeled with anti-CRTH2-PE. A small shift to the right is seen in the histogram showing expression of CRTH2 in transfected cells with an increase in the mean fluorescence intensity from 87.75 in the isotype control to 143.49 in amniocytes, and from 68.84 to 96.97 in myocytes. An example of a GFP control is given for the myocyte transfection, with cells imaged with phase contrast and with the fluorescent microscope to detect GFP transfected cells ( C ). A direct comparison is also shown with non-GFP transfected cells ( D ).

Article Snippet: Antibodies against phospho-p65 (Ser 536), p65 and CRTH2 for western analysis were purchased from Cell Signaling Technology (Beverly, MA), Santa Cruz Biotechnology (Santa Cruz, CA) or Santa Cruz and ProSci Incorporated (Poway, CA) respectively.

Techniques: Transfection, Electroporation, Expressing, Plasmid Preparation, Labeling, Fluorescence, Control, Microscopy, Comparison

Journal: PLoS ONE

Article Title: Chemoattractant Receptor Homologous to the T Helper 2 Cell (CRTH2) Is Not Expressed in Human Amniocytes and Myocytes

doi: 10.1371/journal.pone.0050734

Figure Lengend Snippet: An overview of the mean fluorescence intensities and percentages in the gated cells during detection of transfected CRTH2 in amniocytes and myocytes.

Article Snippet: Antibodies against phospho-p65 (Ser 536), p65 and CRTH2 for western analysis were purchased from Cell Signaling Technology (Beverly, MA), Santa Cruz Biotechnology (Santa Cruz, CA) or Santa Cruz and ProSci Incorporated (Poway, CA) respectively.

Techniques: Fluorescence, Transfection

Journal: PLoS ONE

Article Title: Chemoattractant Receptor Homologous to the T Helper 2 Cell (CRTH2) Is Not Expressed in Human Amniocytes and Myocytes

doi: 10.1371/journal.pone.0050734

Figure Lengend Snippet: PBMCs were treated with 32 µM of 15dPGJ2 for 2 hours with or without preincubation with 2 µM of GSKCRTH2X for 45 mins. Whole cell protein lysate was examined for levels of phosphorylated p65 (p-p65) using immunoblotting. A representative immunoblot from n = 6 samples are shown ( A ). Immunoblots were reprobed for β-actin as an internal loading control. Densitometric analysis of the immunoblots was conducted revealing a complete inhibition of p-p65 levels with 15dPGJ2. Pre-incubation with the CRTH2 antagonist GSKCRTH2X had no effect on inhibition ( B ). J2 = 15dPGJ2, GSKX = GSKCRTH2X. Effect of treatment was examined for statistical significance using ANOVA of repeated measures with Bonferroni’s multiple comparison test; **** P <0.0001.

Article Snippet: Antibodies against phospho-p65 (Ser 536), p65 and CRTH2 for western analysis were purchased from Cell Signaling Technology (Beverly, MA), Santa Cruz Biotechnology (Santa Cruz, CA) or Santa Cruz and ProSci Incorporated (Poway, CA) respectively.

Techniques: Western Blot, Control, Inhibition, Incubation, Comparison

Journal: The Journal of allergy and clinical immunology

Article Title: Prostaglandin D 2 pathway upregulation: Relation to asthma severity, control, and T H 2 inflammation

doi: 10.1016/j.jaci.2013.01.035

Figure Lengend Snippet: A, qRT-PCR of HPGDS mRNA transcripts in epithelial cell brushings relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). *The difference between HCs and the Mild-Mod/ICS group tended to be different (P = .01) but did not reach significance. B, Correlation between HPGDS and tryptase epithelial cell brushing mRNA levels.

Article Snippet: The primers and probes were all purchased from Applied Biosystems (Assays on Demand: HPGDS, Hs00183950_m1; tryptase, Hs02576518_gH; CPA3, Hs00157019_m1; CRTH2, Hs01867513_s1; and DP1, Hs00830594_s1).

Techniques: Quantitative RT-PCR

Journal: The Journal of allergy and clinical immunology

Article Title: Prostaglandin D 2 pathway upregulation: Relation to asthma severity, control, and T H 2 inflammation

doi: 10.1016/j.jaci.2013.01.035

Figure Lengend Snippet: Epithelial brushing cell cytospin preparations. A, Comparison of the percentage of total HPGDS+ cells, as determined by means of IHC. B, Cytospin preparations (fixed in paraformaldehyde) stained with HPGDS antibody. Red arrows, HPGDS+ cells from an SA. Panels are shown at ×40 magnification.

Article Snippet: The primers and probes were all purchased from Applied Biosystems (Assays on Demand: HPGDS, Hs00183950_m1; tryptase, Hs02576518_gH; CPA3, Hs00157019_m1; CRTH2, Hs01867513_s1; and DP1, Hs00830594_s1).

Techniques: Staining

Journal: The Journal of allergy and clinical immunology

Article Title: Prostaglandin D 2 pathway upregulation: Relation to asthma severity, control, and T H 2 inflammation

doi: 10.1016/j.jaci.2013.01.035

Figure Lengend Snippet: qRT-PCR of DP1 and CRTH2 mRNA transcripts in BAL cells relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). *The difference between the Mild-Mod/ICS group versus SAs tended to be different (P = .01) but did not reach significance.

Article Snippet: The primers and probes were all purchased from Applied Biosystems (Assays on Demand: HPGDS, Hs00183950_m1; tryptase, Hs02576518_gH; CPA3, Hs00157019_m1; CRTH2, Hs01867513_s1; and DP1, Hs00830594_s1).

Techniques: Quantitative RT-PCR

Journal: The Journal of allergy and clinical immunology

Article Title: Prostaglandin D 2 pathway upregulation: Relation to asthma severity, control, and T H 2 inflammation

doi: 10.1016/j.jaci.2013.01.035

Figure Lengend Snippet: BAL cell cytospin preparations. A and C, Comparison of the percentage of total BAL cells positive for DP1 (Fig 5, A) and CRTH2 (Fig 5, C), as determined by means of IHC, is shown. B, Cytospin preparations stained with DP1 antibody. Red arrows, DP1+ cells. Upper left panel, HC; lower left panel, Mild-Mod/ICS subject; right panel, SA. Panels are shown at ×40 magnification. D, Cytospin preparations from an SA double stained with CRTH2 and CD3 antibodies. The upper panel is shown at ×40 magnification. The lower panel is shown at ×100 magnification. Red arrow, CRTH2+/CD3+ lymphocyte; blue arrow, CRTH2+ eosinophil; black arrow, CD3+ lymphocyte.

Article Snippet: The primers and probes were all purchased from Applied Biosystems (Assays on Demand: HPGDS, Hs00183950_m1; tryptase, Hs02576518_gH; CPA3, Hs00157019_m1; CRTH2, Hs01867513_s1; and DP1, Hs00830594_s1).

Techniques: Staining

Journal: The Journal of allergy and clinical immunology

Article Title: Prostaglandin D 2 pathway upregulation: Relation to asthma severity, control, and T H 2 inflammation

doi: 10.1016/j.jaci.2013.01.035

Figure Lengend Snippet: History of recent exacerbation and PGD 2 pathway markers in all asthmatic patients

Article Snippet: The primers and probes were all purchased from Applied Biosystems (Assays on Demand: HPGDS, Hs00183950_m1; tryptase, Hs02576518_gH; CPA3, Hs00157019_m1; CRTH2, Hs01867513_s1; and DP1, Hs00830594_s1).

Techniques: Marker

Journal: The Journal of allergy and clinical immunology

Article Title: Prostaglandin D 2 pathway upregulation: Relation to asthma severity, control, and T H 2 inflammation

doi: 10.1016/j.jaci.2013.01.035

Figure Lengend Snippet: Level of NAEPP asthma control and PGD 2 pathway markers in all asthmatic patients

Article Snippet: The primers and probes were all purchased from Applied Biosystems (Assays on Demand: HPGDS, Hs00183950_m1; tryptase, Hs02576518_gH; CPA3, Hs00157019_m1; CRTH2, Hs01867513_s1; and DP1, Hs00830594_s1).

Techniques: Marker